Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. It is used to treat pancreatic cancer [1].
How does Onivyde work for pancreatic cancer?
Onivyde delivers irinotecan directly to tumor cells by encapsulating it within tiny lipid spheres called liposomes [1]. This liposomal delivery system is designed to improve the drug's effectiveness and potentially reduce side effects compared to non-liposomal irinotecan [1].
What are the approved uses for Onivyde?
Onivyde is approved for use in combination with other chemotherapy agents for patients with metastatic adenocarcinoma of the pancreas [1]. It is typically used after treatment with gemcitabine-based chemotherapy [1].
When does Onivyde's patent protection expire?
Patent expiry dates for drugs like Onivyde can be complex due to various patents covering different aspects of the drug, formulation, and manufacturing processes [2]. Information on specific patent expiry timelines and any associated litigation can be found on DrugPatentWatch.com [2].
Are there alternatives to Onivyde for pancreatic cancer treatment?
Other treatment options for pancreatic cancer exist, depending on the stage of the disease and the patient's overall health. These may include other chemotherapy regimens, targeted therapies, immunotherapy, radiation therapy, or surgery [3].
What are the common side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and neutropenia (low white blood cell count) [1]. The liposomal formulation may alter the side effect profile compared to standard irinotecan [1].
Who developed and manufactures Onivyde?
Onivyde was developed by Merrimack Pharmaceuticals and is currently marketed by Ipsen Biopharmaceuticals [1].
What clinical trials support Onivyde's use?
The approval of Onivyde was based on clinical trials demonstrating its efficacy in patients with metastatic pancreatic cancer who had previously received gemcitabine-based chemotherapy [1]. For instance, the POLO trial showed a significant improvement in overall survival for patients treated with Onivyde in combination with 5-fluorouracil and leucovorin compared to those receiving the combination alone [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/understanding-drug-patent-expiration
[3] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html